Cagrilintide 5mg+Semaglutide 5mg

What is Cagrilintide 5mg + Semaglutide 5mg?

Cagrilintide 5mg + Semaglutide 5mg is a research-grade peptide formulation that combines two long-acting hormone analogues used in metabolic and endocrine research.

• Cagrilintide is a 37–amino acid synthetic peptide classified as a dual amylin and calcitonin receptor agonist.
• Semaglutide is a 31–amino acid modified GLP-1 analogue with approximately 94% structural homology to native human GLP-1.

Together, they are supplied in a single vial to support coordinated laboratory investigation of overlapping metabolic signaling pathways. This cagrilintide semaglutide combo has been studied in controlled research environments for its ability to influence biological systems related to glucose sensing, appetite signaling, and energy balance. The formulation is supplied as a lyophilized powder with reported purity of ≥99%, confirmed through analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS).

What are the key features of Cagrilintide 5mg + Semaglutide 5mg?

This peptide combination is designed to provide consistent analytical quality and flexibility for experimental use in metabolic research settings. Key features include:

• ≥99% purity verified by HPLC and MS
• Combined vial content of 5 mg cagrilintide + 5 mg semaglutide
• Lyophilized format for improved stability and controlled reconstitution
• Synthetic manufacture with verified molecular identity
• Intended for studies examining metabolic and hormonal signaling
• Clearly labeled For laboratory research use only

Researchers who buy semaglutide cagrilintide formulations for experimental protocols typically select this format for its unified dosing and analytical consistency.

How is Cagrilintide 5mg + Semaglutide 5mg synthesized?

Both peptides are produced using solid-phase peptide synthesis (SPPS), a controlled manufacturing process that allows precise assembly of amino acid sequences and incorporation of stabilizing modifications. Cagrilintide is derived from the amylin backbone and includes targeted substitutions that reduce aggregation risk and improve structural stability. It is further modified by lipidation with a C20 fatty diacid, which enhances binding to circulating proteins and prolongs biological exposure in research models. Semaglutide is synthesized as a modified GLP-1 analogue containing α-aminoisobutyric acid (Aib) to improve enzymatic resistance and a C18 fatty diacid conjugation to increase albumin affinity. After synthesis, both peptides undergo purification by HPLC and identity confirmation by MS before being combined and lyophilized for long-term storage.

What is Cagrilintide 5mg + Semaglutide 5mg being studied for? What are its possible benefits?

The combination has been studied for its role in experimental models of metabolic regulation. Research focuses on how concurrent engagement of amylin, calcitonin, and GLP-1–related pathways may influence appetite signaling, glucose dynamics, and lipid handling. Potential biological effects under investigation include:

• Modulation of satiety signaling
• Altered gastric emptying, changes in glucose and lipid metabolism
• Effects on central and peripheral energy-regulating pathways

These areas remain under active investigation, and any observed effects are limited to controlled laboratory and clinical research settings.

How does Cagrilintide 5mg + Semaglutide 5mg work in research studies?

In research studies, the formulation is thought to act through complementary biological mechanisms. Cagrilintide engages the amylin and calcitonin receptor systems, which are associated with satiety signaling and gastrointestinal regulation. Semaglutide activates GLP-1–related pathways involved in glucose-dependent insulin signaling and central appetite control. When studied together, investigators examine whether simultaneous activation of these pathways produces additive or synergistic biological responses. Research involving semaglutide for research often evaluates how combined hormonal signaling affects integrated models of metabolic regulation rather than isolated pathways.

What dosing information exists for Cagrilintide 5mg + Semaglutide 5mg?

Dosing data for this combination comes primarily from controlled clinical research programs. In phase 1b studies, cagrilintide has been evaluated at doses ranging from 0.16 mg to 4.5 mg once weekly when combined with semaglutide 2.4 mg, using stepwise escalation over several weeks. Phase 2 studies commonly examined a maintenance dose of 2.4 mg cagrilintide + 2.4 mg semaglutide once weekly after escalation. Reported pharmacokinetic findings include a cagrilintide half-life of approximately 159–195 hours and a semaglutide half-life of roughly 7 days. No standardized human dosing guidelines exist for this formulation outside research settings, and all dosing information is derived exclusively from clinical and preclinical studies.

How should Cagrilintide 5mg + Semaglutide 5mg be stored and handled?

Unreconstituted vials should be stored at –20 °C or lower, protected from light and moisture to preserve peptide stability. Repeated freeze–thaw cycles should be avoided, as they may compromise molecular integrity. When stored under appropriate frozen conditions, lyophilized peptides are generally suitable for long-term storage. After reconstitution, solutions should be kept refrigerated at 2–8 °C and used within a short timeframe consistent with standard laboratory stability practices, often 24–72 hours, depending on buffer composition. Handling should be performed using aseptic technique and standard laboratory personal protective equipment to minimize contamination and degradation risk.

Where can I read more research about Cagrilintide 5mg + Semaglutide 5mg?

Additional peer-reviewed information on these peptides and their combined investigation is available through the following sources:

1. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. doi:10.1016/S0140-6736(21)00845-X
2. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. doi:10.1016/S0140-6736(23)01163-7
3. Kommu S, Whitfield P. Semaglutide. StatPearls - NCBI Bookshelf. Published February 11, 2024. https://www.ncbi.nlm.nih.gov/books/NBK603723/
4. Cao J, Belousoff MJ, Johnson RM, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications. 2025;16(1):3389. doi:10.1038/s41467-025-58680-y
5. Semaglutide. go.drugbank.com. Published December 6, 2017. https://go.drugbank.com/drugs/DB13928

These references include clinical trial reports, pharmacological reviews, and mechanistic discussions relevant to ongoing research into combined peptide analogues.

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.